HLB Pharmaceutical said on the 14th it will roll out a prostate cancer treatment in June. Prostate cancer is common among older men in Korea. In the early stages there are almost no symptoms, so the timing of diagnosis is often missed.
The company recently received approval from the Ministery of Food and Drug Safety for Elbitandi soft capsules, a prostate cancer treatment. It is a generic drug of Astellas Pharma Korea's Xtandi. It works by inhibiting androgen receptor signaling.
An HLB Pharmaceutical official said, "This is the first step in ramping up our anticancer generic drug business," and added, "We will carry out general-hospital-tailored marketing so we can compete with the original drug."
※ This article has been translated by AI. Share your feedback here.